(Q33946929)

30 July 2017

title

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial (English)

1 reference

30 July 2017

main subject

phase II clinical trial

0 references

cabozantinib

1 reference

ChEBI release 2020-05-28

1 reference

18

Patrick Schöffski

1 reference

30 July 2017

8

Eric J Small

1 reference

30 July 2017

David C Smith

1

1 reference

30 July 2017

Matthew R Smith

2

1 reference

30 July 2017

Christopher Sweeney

3

1 reference

30 July 2017

Aymen A Elfiky

4

1 reference

30 July 2017

Christopher Logothetis

5

1 reference

30 July 2017

Paul G Corn

6

1 reference

30 July 2017

Nicholas J Vogelzang

7

1 reference

30 July 2017

Andrea L Harzstark

9

1 reference

30 July 2017

Michael S Gordon

10

1 reference

30 July 2017

Ulka N Vaishampayan

11

1 reference

30 July 2017

Naomi B Haas

12

1 reference

30 July 2017

Alexander I Spira

13

1 reference

30 July 2017

Primo N Lara

14

1 reference

30 July 2017

Chia-Chi Lin

15

1 reference

30 July 2017

Sandy Srinivas

16

1 reference

30 July 2017

Avishay Sella

17

1 reference

30 July 2017

Christian Scheffold

19

1 reference

30 July 2017

Aaron L Weitzman

20

1 reference

30 July 2017

Maha Hussain

21

1 reference

30 July 2017

language of work or name

English

0 references

publication date

19 November 2012

1 reference

Journal of Clinical Oncology

30 July 2017

published in

1 reference

30 July 2017

volume

31

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

412-419

1 reference

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

MET and VEGF: synergistic targets in castration-resistant prostate cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

Vascular endothelial growth factor regulates osteoblast survival - evidence for an autocrine feedback mechanism

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

Involvement of hepatocyte growth factor in the development of bone metastasis of a mouse mammary cancer cell line, BALB/c-MC.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

Multiple roles of vascular endothelial growth factor (VEGF) in skeletal development, growth, and repair

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

High expression of the Met receptor in prostate cancer metastasis to bone

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

c-met proto-oncogene expression in benign and malignant human prostate tissues

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

A phase II clinical trial of sorafenib in androgen-independent prostate cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

Regulation of release of hepatocyte growth factor from human promyelocytic leukemia cells, HL-60, by 1,25-dihydroxyvitamin D3, 12-O-tetradecanoylphorbol 13-acetate, and dibutyryl cyclic adenosine monophosphate.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110249

Prognostic Significance of Plasma Scatter Factor/Hepatocyte Growth Factor Levels in Patients with Metastatic Hormone- Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 150005/9480

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23169517

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23169517

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23169517

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2012.45.0494

1 reference

30 July 2017

1 reference

30 July 2017

1 reference